Pulse Pressure and Outcomes After Out-of-Hospital Cardiac Arrest (STEP-PRESS)
STEP-PRESS: Association of Pulse Pressure With Early Mortality and Biomarker Outcomes After Out-of-Hospital Cardiac Arrest
Visão geral do estudo
Status
Descrição detalhada
STEP-PRESS is a predefined exploratory observational substudy nested within STEPCARE, an international, multicenter, randomized factorial trial of intensive-care strategies after out-of-hospital cardiac arrest. STEPCARE is registered as NCT05564754. The STEPCARE biomarker substudy is registered as NCT06471972.
STEP-PRESS will use data collected within the STEPCARE trial and applicable substudy approvals. No additional intervention, patient contact, or deviation from STEPCARE clinical management is planned for STEP-PRESS.
The source population will consist of randomized STEPCARE participants, excluding consent withdrawals. Pulse pressure will be calculated as systolic blood pressure minus diastolic blood pressure using recorded STEPCARE blood-pressure values. The primary exposure is cumulative low pulse-pressure burden, defined as the number of hours during 0 to 12 hours after randomization in which interpolated pulse pressure is below 40 mmHg.
The primary analysis population will be restricted to participants alive 12 hours after randomization, without mechanical circulatory support initiated before or within 24 hours after randomization, and with at least three valid recorded blood-pressure observations during 0 to 12 hours after randomization.
The primary outcome is all-cause mortality from the 12-hour landmark to day 7. Key secondary outcomes include mortality in a 24-hour landmark analysis, neurological biomarker endpoints, 30-day mortality, 6-month survival, and 6-month functional outcome. Six-month poor functional outcome will follow the parent STEPCARE definition of modified Rankin Scale score 4 to 6.
All STEP-PRESS objectives are associational. The substudy is not designed to test whether modifying pulse pressure improves outcomes.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Malmö, Suécia, 20205
- Department of Intensive Care, Skåne University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Randomized in the STEPCARE trial.
- Out-of-hospital cardiac arrest.
- Stable return of spontaneous circulation, defined in the parent STEPCARE protocol as at least 20 minutes without chest compressions.
- Unconsciousness after sustained return of spontaneous circulation, defined as not being able to obey verbal commands, or intubated and sedated because of agitation.
- Eligible for intensive care without restrictions or limitations.
- Included in STEPCARE within the parent-trial inclusion window.
- For STEP-PRESS analyses, availability of recorded STEPCARE blood-pressure data sufficient to calculate pulse pressure for the relevant analysis population.
- For the primary STEP-PRESS analysis population: alive 12 hours after randomization, without mechanical circulatory support initiated before or within 24 hours after randomization, and with at least three valid recorded blood-pressure observations during 0 to 12 hours after randomization.
Exclusion Criteria:
- Withdrawal of consent for use of STEPCARE trial data.
- Trauma or hemorrhage as the presumed cause of cardiac arrest.
- Suspected or confirmed intracranial hemorrhage.
- On extracorporeal membrane oxygenation before STEPCARE randomization.
- Pregnancy.
- Previously randomized in the STEPCARE trial.
- For STEP-PRESS primary and 24-hour landmark analyses: mechanical circulatory support initiated before or within 24 hours after randomization.
- For endpoint-specific analyses: missing data required to define the relevant exposure, outcome, or biomarker endpoint.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
STEPCARE Participants
Randomized STEPCARE participants included in the STEP-PRESS source population, excluding consent withdrawals.
STEP-PRESS will evaluate pulse-pressure burden as an observational exposure using recorded STEPCARE blood-pressure values.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-Cause Mortality From 12 Hours to Day 7
Prazo: From 12 hours after randomization through day 7 after randomization
|
Death from any cause occurring after the 12-hour landmark and through day 7 after randomization, evaluated in relation to cumulative low pulse-pressure burden below 40 mmHg during 0 to 12 hours after randomization.
|
From 12 hours after randomization through day 7 after randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-Cause Mortality in the 24-Hour Landmark Analysis
Prazo: From 24 hours after randomization through day 7 after randomization
|
Death from any cause occurring after the 24-hour landmark and through day 7 after randomization, evaluated in relation to cumulative low pulse-pressure burden below 40 mmHg during 0 to 24 hours after randomization.
|
From 24 hours after randomization through day 7 after randomization
|
|
Neurofilament Light Level at 12 Hours
Prazo: 12 hours after randomization
|
Neurofilament light concentration at 12 hours after randomization, analyzed among participants in the STEPCARE biomarker substudy with available biomarker data.
|
12 hours after randomization
|
|
Neuron-Specific Enolase Level at 48 Hours
Prazo: 48 hours after randomization
|
Neuron-specific enolase concentration at 48 hours after randomization, analyzed using available STEPCARE measurements.
|
48 hours after randomization
|
|
30-Day All-Cause Mortality
Prazo: 30 days after randomization
|
Death from any cause within 30 days after randomization.
|
30 days after randomization
|
|
6-Month Survival
Prazo: 6 months after randomization
|
Survival status at 6 months after randomization.
|
6 months after randomization
|
|
Poor Functional Outcome at 6 Months
Prazo: 6 months after randomization
|
Poor functional outcome at 6 months after randomization, defined according to the parent STEPCARE definition as modified Rankin Scale score 4 to 6.
|
6 months after randomization
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Complicações pós-operatórias
- Processos Patológicos
- Doenças cardíacas
- Parada cardíaca
- Lesões cerebrais
- Lesão de Reperfusão
- Condições Patológicas, Sinais e Sintomas
- Síndrome Pós-Parada Cardíaca
- Parada Cardíaca Fora do Hospital
- Doença de Charcot-Marie-Tooth, tipo 1F
Outros números de identificação do estudo
- STEP-PRESS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .